The National Multiple Sclerosis Society‘s Lone Star Chapter, which is sponsoring the nonprofit organization’s annual Houston-area Walk MS fundraisers, has announced that Woodlands-based biopharmaceutical company Opexa Therapeutics, a company currently developing personalized immunotherapies for multiple sclerosis (MS), will also support the fundraising effort.
This is the fourth consecutive year that the Lone Star Chapter of the National Multiple Sclerosis Society has served as a sponsor of the event in Houston, but this year, Opexa also decided to join the event which helps about 68,000 patients suffering from the disease. The Houston-area fundraisers take place between October and November at four locations. This year, one of the fundraising locations will be at Opexa’s corporate headquarters in The Woodlands.
“Opexa is proud to be a partner of the National MS Society’s Houston area Walk MS events,” said the President and Chief Executive Officer of Opexa, Neil K. Warma. “We are committed to helping the Society support critical programs and services to improve the quality of life for people affected by MS. We are dedicated to developing a personalized therapy for Secondary Progressive MS, and these events offer the unique opportunity for those of us in the Company to meet people living with MS and their families, which provides us with tremendous motivation.”
The walk will serve as a meeting point for the MS Movement, a community coming together to raise funds and celebrate hope for the future for the more than 2.3 million people living with MS worldwide. Last year, the event was held in the South Central Chapter’s territory, in which The Lone Star Chapter is also included, and brought together more than 25,000 people who helped raise $3.2 million for the National Multiple Sclerosis Society. Since 1988, Walk MS has been organized nationally, and has already raised more than $770 million to support programs, research, and new therapies.
Opexa’s lead MS product is Tcelna, a breakthrough T-cell immunotherapy for the treatment of MS. The company recently announced the end of patient enrollment for their Phase IIb clinical trial to test a drug as a viable treatment for Secondary Progressive MS.